Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Testosterone oral - TesoRx

Drug Profile

Testosterone oral - TesoRx

Alternative Names: CDGP therapy - TesoRx; TSX-002

Latest Information Update: 19 Dec 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Western University of Health Sciences
  • Developer TesoRx
  • Class Anabolic steroids; Androstenols; Erectile dysfunction therapies; Hormonal replacements; Small molecules; Testosterone congeners
  • Mechanism of Action Testosterone congener stimulants; Testosterone replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Hypogonadism
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Hypogonadism

Most Recent Events

  • 19 Dec 2023 Discontinued - Phase-II for Hypogonadism (In adolescents) in USA (PO) (TesoRx pipeline, December 2023)
  • 09 Sep 2020 Phase-II development is ongoing in Hypogonadism (In adolescents) in USA (PO) before September 2020 (TesoRx pipeline, September 2020)
  • 01 Dec 2017 A phase II study in constitutional delay in growth and puberty is planned for adolescent males in Japan in 2018
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top